Evidence map›Paper›PMID 30871013›Full record

ArticleJournal of clinical medicine2019

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer.

Ion Cristóbal, Blanca Torrejón, Jaime Rubio, Andrea Santos, Manuel Pedregal, Cristina Caramés, Sandra Zazo, Melani Luque, Marta Sanz-Alvarez, Juan Madoz-Gúrpide and 2 more

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ion CristóbalCancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. ion.cristobal@fjd.es.
Blanca TorrejónCancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. blanca.torrejon@quironsalud.es.
Jaime RubioCancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. jaime.rubiop@quironsalud.es.
Andrea SantosTranslational Oncology Division, Oncohealth Institute, IIS- Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. andreasantos.asc@gmail.com.
Manuel PedregalCancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. manuel.pedregal@quironsalud.es.
Cristina CaramésCancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. ccarames@fjd.es.ORCID 0000-0002-5748-7628
Sandra ZazoPathology Department, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. szazo@fjd.es.
Melani LuquePathology Department, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. melani.luque@quironsalud.es.
Marta Sanz-AlvarezPathology Department, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. marta.sanza@quironsalud.es.
Juan Madoz-GúrpidePathology Department, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. jmadoz@fjd.es.
Federico RojoPathology Department, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. frojo@fjd.es.ORCID 0000-0001-9989-0290
Jesús García-FoncillasTranslational Oncology Division, Oncohealth Institute, IIS- Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain. jesus.garciafoncillas@oncohealth.eu.

Funding

Instituto de Salud Carlos III PI15/00934Instituto de Salud Carlos III PI16/01468
6 · The paper itself

Abstract

SET nuclear proto-oncogene (SET) deregulation is a novel molecular target in metastatic colorectal cancer (CRC). However, its role in CRC progression and its potential clinical impact in early-stage CRC patients remain unknown. Here, we studied the biological effects of SET on migration using wound-healing and transwell assays, and anchorage-independent cell growth using soft agar colony formation assays after ectopic SET modulation. SET was analyzed by immuno-staining in 231 early-stage CRC patients, and miR-199b expression was quantified by real-time PCR in a set of CRC patients. Interestingly, SET enhances cell migration, markedly affects the colony-forming ability, promotes epithelial to mesenchymal transition, and induces the expression of the MYC proto-oncogene (c-MYC) in CRC cells. SET overexpression was detected in 15.4% of cases and was associated with worse Eastern Cooperative Oncology Group (ECOG) status (

Indexed as

early-stage colorectal cancer (CRC)protein phosphatase 2A (PP2A)SET

Identifiers

PMID30871013
PMCPMC6463201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.